Biomarcadores y Práctica Clínica

1. MARTÍN-VENTURA JL, BLANCO-COLIO LM, TUÑÓN J, MUÑOZ-GARCÍA B, MADRIGAL-MATUTE J, MORENO JA et al. Biomarkers in cardiovascular medicine. Rev Esp Cardiol 2009; 62: 677-688.

https://doi.org/10.1016/S0300-8932(09)71335-1

2. STRIMBU K, TAVEL JA. What are biomarkers? Curr Opin HIV AIDS 2010; 5: 463-466.

https://doi.org/10.1097/COH.0b013e32833ed177

3. RICHARDS AM. New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 2010; 63: 635-639.

https://doi.org/10.1016/S1885-5857(10)70137-7

4. IQBAL N, ALIM KS, ARAMIN H, IQBAL F, GREEN E, HIGGINBOTHAM E et al. Novel biomarkers for heart failure. Expert Rev Cardiovasc Ther 2013; 11: 1155-1169.

https://doi.org/10.1586/14779072.2013.832476

5. CALVO-RODRÍGUEZ S, MONTERO-PÉREZ FJ, GARCÍA OLID A, BAENA-DELGADO E, GALLARDO-VALVERDE JM, CALDERÓN DE LA BARCA-GÁZQUEZ JM et al. Proteína C reactiva y lactato deshidrogenasa en el diagnóstico de la obstrucción intestinal en un servicio de urgencias. An Sist Sanit Navar 2016; 39:

6. CEVIKEL MH, OZGÜN H, BOYLU S, DEMIRKIRAN AE, AYDIN N, SARI C et al. C-reactive protein may be a marker of bacterial translocation in experimental intestinal obstruction. ANZ J Surg 2004; 74: 900-904.

https://doi.org/10.1111/j.1445-1433.2003.02681.x

7. HEIKKILÄ K, EBRAHIM S, LAWLOR DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61: 824-833.

https://doi.org/10.1136/jech.2006.051292

8. PAREDES CA, VEGA J, DE LEÓN A, KANACRI A, CASTRO P, BAEZA R. Clinical usefulness of biomarkers in cardiac failure. Rev Med Chil 2013; 141: 1560-1569.

https://doi.org/10.4067/S0034-98872013001200010

9. VENUGOPAL SK, DEVARAJ S, JIALAL I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-37.

https://doi.org/10.1097/00041552-200501000-00006

10. WETTERSTEN N, MAISEL AS. Biomarkers for heart failure: An update for practitioners of internal medicine. Am J Med 2016 pii: S0002-9343(16)30075-4. doi: 10.1016/j.amjmed.2016.01.013.

https://doi.org/10.1016/j.amjmed.2016.01.013

11. MALLICK A, JANUZZI JL JR. Biomarkers in acute heart failure. Rev Esp Cardiol 2015; 68: 514-525.

https://doi.org/10.1016/j.recesp.2015.02.009

12. VILLANUEVA MP, MOLLAR A, PALAU P, CARRATALÁ A, NÚÑEZ E, SANTAS E et al. Procalcitonin and long-term prognosis after an admission for acute heart failure. Eur J Intern Med 2015; 26: 42-48.

https://doi.org/10.1016/j.ejim.2014.12.009

13. MOLLAR A, VILLANUEVA MP, CARRATALÁ A, NÚÑEZ E, SANCHIS J, NÚÑEZ J. Determinants of procalcitonin concentration in acute heart failure. Int J Cardiol 2014; 177: 532-534.

https://doi.org/10.1016/j.ijcard.2014.08.106

14. VON HAEHLING S, SCHEFOLD JC, LAINSCAK M, DOEHNER W, ANKER SD. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 2009; 5: 549-560.

https://doi.org/10.1016/j.hfc.2009.04.001

15. CANBAY A, CELEBI OO, CELEBI S, AYDOGDU S, DIKER E. Procalcitonin: a marker of heart failure. Acta Cardiol 2015; 70: 473-478.

https://doi.org/10.1080/AC.70.4.3096896

16. LONCAR G, TSCHOLL V, TAHIROVIC E, SEKULARAC N, MARX A, OBRADOVIC D et al. Should procalcitonin be measured routinely in acute decompensated heart failure? Biomark Med 2015; 9: 651-659.

https://doi.org/10.2217/bmm.15.29